enGene Holdings Inc. (NASDAQ:ENGN) Given Consensus Recommendation of "Hold" by Brokerages

Key Points

• Analyst consensus is “Hold”: Of 14 analysts covering enGene, eight rate the stock a hold, four recommend buying and two recommend selling. The average 12-month price target is $11.05.
• Recent analyst sentiment weakened significantly: Several firms downgraded enGene on May 8, including Wells Fargo, which cut its price target from $25 to $2; Raymond James set a $4 target.
• ENGN remains under pressure: Shares opened at $1.78, near the $1.40 one-year low and well below the $12.25 high. The company reported a quarterly loss of $0.43 per share, though that beat estimates of a $0.48 loss.

Shares of enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) have been given an average recommendation of "Hold" by the fourteen research firms that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, eight have given a hold recommendation and four have given a buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $11.0455.

Several analysts have commented on ENGN shares. Citizens Jmp downgraded enGene from an "outperform" rating to a "market perform" rating in a research note on Friday, May 8th. Citigroup downgraded shares of enGene from a "market outperform" rating to a "market perform" rating in a report on Friday, May 8th. Wells Fargo & Company restated an "equal weight" rating and issued a $2.00 price target (down from $25.00) on shares of enGene in a research report on Friday, May 8th. Raymond James Financial downgraded enGene from a "strong-buy" rating to an "outperform" rating and set a $4.00 price objective for the company. in a research report on Friday, May 8th. Finally, Wall Street Zen raised shares of enGene from a "strong sell" rating to a "sell" rating in a research note on Saturday, August 15th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ENGN. Cresset Asset Management LLC purchased a new position in enGene in the 2nd quarter valued at about $36,000. Raymond James Financial Inc. increased its position in shares of enGene by 383.6% during the third quarter. Raymond James Financial Inc. now owns 10,000 shares of the company's stock worth $68,000 after acquiring an additional 7,932 shares during the last quarter. Paloma Partners Management Co acquired a new position in shares of enGene in the second quarter worth about $38,000. Jump Financial LLC acquired a new position in shares of enGene in the fourth quarter worth about $121,000. Finally, Millennium Management LLC lifted its stake in shares of enGene by 57.3% in the third quarter. Millennium Management LLC now owns 20,502 shares of the company's stock worth $140,000 after acquiring an additional 7,472 shares in the last quarter. 64.16% of the stock is currently owned by hedge funds and other institutional investors.

enGene Stock Up 0.6%

ENGN opened at $1.78 on Friday. The stock has a market capitalization of $119.24 million, a P/E ratio of -0.82 and a beta of -0.28. enGene has a one year low of $1.40 and a one year high of $12.25. The business's 50-day simple moving average is $1.80 and its 200-day simple moving average is $4.76. The company has a debt-to-equity ratio of 0.10, a quick ratio of 12.57 and a current ratio of 12.57.

enGene (NASDAQ:ENGN - Get Free Report) last issued its quarterly earnings data on Monday, June 15th. The company reported ($0.43) earnings per share for the quarter, beating analysts' consensus estimates of ($0.48) by $0.05. During the same period in the previous year, the firm posted $0.51 earnings per share. Analysts anticipate that enGene will post -1.84 EPS for the current year.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source